Yamanouchi Pharmaceutical
 |
|
| Public KK | |
| Traded as | |
| Industry | Pharmaceutical |
| Predecessors | Yamanouchi Pharmaceutical Fujisawa Pharmaceutical (Merged in 2005) |
| Founded | 2005 |
| Headquarters | 2-5-1, Nihonbashi-Honcho, Chūō-ku, Tokyo 103-8411, Japan |
|
Key people
|
Yoshihiko Hatanaka (President and CEO) |
| Products |
|
| Revenue |
 US$11,060,000,000 (FY 2013) |
| Profit |
US$1,280,000,000 (¥1,139,000,000,000) (FY 2013) |
| Total assets | $14.86 billion (2016) |
|
Number of employees
|
17,649 (consolidated as of March 2014) |
| Subsidiaries | Astellas US |
| Website | Official website |
|
Footnotes / references |
|
Astellas Pharma Inc. (アステラス製薬株式会社 Asuterasu Seiyaku Kabushiki-gaisha?) is a Japanese pharmaceutical company, formed on 1 April 2005 from the merger of Yamanouchi Pharmaceutical Co., Ltd. (山之内製薬株式会社 Yamanouchi Seiyaku Kabushiki-gaisha?) and Fujisawa Pharmaceutical Co., Ltd. (藤沢薬品工業株式会社 Fujisawa Yakuhin Kōgyō Kabushiki-gaisha?).
Astellas is a member of the Mitsubishi UFJ Financial Group (MUFJ) keiretsu.
Fujisawa Shoten was started in 1894 by Tomokichi Fujisawa in Osaka, and was renamed Fujisawa Pharmaceutical Co. in 1943. Yamanouchi Yakuhin Shokai was started in 1923 by Kenji Yamanouchi in Osaka. The company was renamed Yamanouchi Pharmaceutical Co. in 1940 and moved to Tokyo in 1942. Both companies started their overseas expansion at about the same time, opening offices in Taiwan in 1962 and 1963, respectively, and in the United States and Europe from 1977 onwards.
Fujisawa acquired Lyphomed in 1990 and thereafter established its US R&D center in Deerfield, Illinois. Yamanouchi's R&D center in Leiderdorp was established with the acquisition of the pharmaceutical division of Royal Gist Brocades in 1991. Fujisawa and Yamanouchi combined in a "merger of equals," forming Astellas Pharma on 1 April 2005. At least some of its older products continue to be distributed under the original brand, ostensibly due to high brand-name recognition. Astellas had a collaboration agreement with CoMentis from 2008 to 2014 focused on development of beta-secretase inhibitor therapeutics for Alzheimer's disease.
...
Wikipedia